Feces multi-target methylation detection kit for digestive tract tumor diagnosis, screening model construction method and diagnosis system
Through the multi-target fecal DNA methylation detection method, specific primers and probes were used to detect genes such as PDX1, COL4A2-1, FGF5, etc., combined with machine learning models, it solved the problem of the inability to accurately detect multiple digestive tract tumors in the existing technology in the early stage. The problem of this achieves the early accurate diagnosis and localization of gastrointestinal tumors.
Patent Information
- Application Number
- CN202411190363.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-22
AI Technical Summary
The existing fecal DNA methylation detection methods are mainly used to detect a single type of colorectal cancer. There is a lack of multi-target detection methods for all-gastrointestinal tumors, resulting in the inability to accurately detect and locate gastrointestinal tumors in the early stage.
Develop a multi-target fecal DNA methylation detection method, and use qPCR and machine learning models to construct digestion by designing specific primers and probes. The screening model for people with tract tumor risk can achieve non-invasive and highly sensitive early diagnosis.
It has achieved early accurate detection and location of a variety of gastrointestinal tumors, improved the sensitivity and accuracy of detection, and provided a basis for early screening, early diagnosis and early treatment of gastrointestinal tumors.
Smart Images

Figure BDA0005014936990000031 
Figure BDA0005014936990000051 
Figure HDA0005014937000000011
Abstract
Description
Technical Field
[0001] The present application relates to the field of biomedicine, and more specifically, to a stool multi-target methylation detection kit, a screening model construction method and a diagnostic system for diagnosing digestive tract tumors. Background Art
[0002] Digestive tract tumors, including colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, etc., are among the malignant tumors with high morbidity and mortality rates worldwide. According to the latest statistics, there are approximately millions of new cases and a large number of deaths related to digestive tract tumors each year worldwide, accounting for one-third of the world's cancer burden. Liquid biopsy (SEPT9 methylation) and "Cologuard" have been approved by the FDA for early detection of colorectal cancer (CRC), but not for other digestive tract tumors. In addition, although CancerSEEK can be used to detect a variety of digestive tract tumors, it has low sensitivity, is expensive, and cannot locate tissue sources.
[0003] In recent years, with the rapid development of molecular biology technology, DNA methylation, as an important epigenetic modification in the process of tumor development, has gradually become a hot research field for early diagnosis of tumors. DNA methylation refers to the process of transferring a methyl group to the 5th carbon atom of cytosine using S-adenosylmethionine as a methyl donor under the catalysis of DNA methyltransferase to form 5-methylcytosine. During tumor development, the DNA methylation pattern of specific genes will change, and this change often precedes the morphological changes of the tumor, so it has the potential to serve as an early diagnostic marker for tumors.
[0004] Feces is a promising sample for gastrointestinal tumor detection because it contains a large amount of circulating free DNA from host shed cells and gastrointestinal tumor cells. Therefore, non-invasive screening methods based on fecal DNA methylation detection have the advantages of high accuracy, simple operation, high patient acceptance, and good repeatability, and have gradually become a research hotspot for early screening of gastrointestinal tumors. However, existing fecal DNA methylation detection methods often detect a single cancer type, CRC, and lack reagents for detecting all cancer types.
[0005] Based on the above background, the development of a highly sensitive, non-invasive, multi-target fecal DNA methylation detection method is of great significance for the early detection and localization of gastrointestinal tumors. Summary of the invention
[0006] The purpose of the present invention is to develop a sensitive, non-invasive multi-target fecal DNA methylation detection method for early detection and positioning of gastrointestinal tumors.
[0007] In order to achieve the above-mentioned invention object, this application provides the following technical solutions:
[0008] In a first aspect, the present application provides the use of a stool DNA methylation detection reagent in the preparation of a digestive tract tumor diagnosis product, wherein the reagent comprises a combination of the following multiple groups of primer pairs:
[0009] The primer pair used to detect the PDX1 gene, the sequences of which are shown in SEQ ID NOs. 1 to 2;
[0010] The primer pair used to detect the COL4A2-1 gene, whose sequences are shown in SEQ ID NOs. 4 to 5;
[0011] The primer pair used to detect the FGF5 gene has sequences shown in SEQ ID NOs. 7-8.
[0012] Furthermore, the reagent also includes a combination of the following probes:
[0013] A probe for detecting the PDX1 gene, the sequence of which is shown in SEQ ID NO.3;
[0014] A probe for detecting COL4A2-1 gene, the sequence of which is shown in SEQ ID NO.6;
[0015] The sequence of the probe used to detect the FGF5 gene is shown in SEQ ID NO.9.
[0016] Furthermore, the reagent also includes a primer pair for detecting the internal reference gene GAPDH, and the sequence thereof is shown in SEQ ID NOs. 10-11.
[0017] Furthermore, the reagent also includes a probe for detecting the internal reference gene GAPDH, the sequence of which is shown in SEQ ID NO.12.
[0018] In a second aspect, the present application provides a digestive tract tumor diagnosis product, comprising any fecal DNA methylation detection reagent described in the first aspect.
[0019] In a third aspect, the present application provides a method for constructing a screening model for a population at risk of digestive tract tumors, comprising the following steps:
[0020] Step 1, collecting stool samples for constructing a screening model for gastrointestinal tumor risk groups;
[0021] Step 2, using any of the stool DNA methylation detection reagents described in the first aspect to perform qPCR detection on the stool samples collected in step 1 to obtain the Ct value of the stool DNA of each sample;
[0022] Step 3, calculate the ΔCt value, ΔCt=Ct(target gene)-Ct(GAPDH), and perform scoring.
[0023] Furthermore, the method further comprises the following steps:
[0024] Step 4, use the △Ct value obtained in step 3 to build a machine learning model, use a multivariate logistic regression model to build a model, and set relevant thresholds to obtain a screening model for people at risk of gastrointestinal tumors.
[0025] In a fourth aspect, the present application provides an application of a model obtained by the modeling method described in the third aspect in the preparation of a gastrointestinal tumor diagnostic product.
[0026] In a fifth aspect, the present application provides a digestive tract tumor diagnosis system, comprising:
[0027] Data module: used to obtain the △Ct value data of qPCR of fecal DNA of the sample to be tested
[0028] Scoring module: obtaining the score of the sample to be tested by the model obtained by the modeling method described in the third aspect;
[0029] Judgment module: Use the threshold to judge the score of the sample to be tested. If it is greater than the threshold, it is judged as positive, and if it is less than the threshold, it is judged as negative.
[0030] In summary, this application has the following beneficial effects:
[0031] Multi-target fecal DNA methylation testing is non-invasive, convenient, and highly sensitive. It can accurately detect and identify the tissue of origin of gastrointestinal cancer at an early stage, providing a basis for early screening, diagnosis, and treatment of gastrointestinal tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 : Detection flow chart in Example 2 of the present application.
[0033] Figure 2 : Detection flow chart in Example 3 of the present application. DETAILED DESCRIPTION
[0034] The technical scheme and effects of the present application are further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the invention, rather than to limit the invention.
[0035] Example 1: Primer and probe design
[0036] By querying gene annotation databases such as NCBI, Ensembl and UCSC, the target gene and its upstream and downstream sequences within 5kb are obtained. Then the CpG island enriched region is screened out for primer probe design. According to the design principle of methylation-specific PCR primers and probes, the C in the CpG island is considered to be methylated, while the C in the non-CpG region is not methylated. After obtaining the simulated bisulfite treatment sequence, conventional primer and probe design tools are used for design and chemical synthesis. The specific primer and probe sequence information of the three fecal DNA targets (PDX1, COL4A2-1 and FGF5) of the present invention is shown in Table 1 (primers and probes containing internal reference GAPDH).
[0037] Table 1 Specific primers and probe sequences for fecal DNA
[0038]
[0039] Example 2: Construction of Model 1
[0040] This study recruited 124 untreated patients with histological diagnosis of gastrointestinal tumors and 92 healthy controls who underwent gastrointestinal tumor-related examinations every 3 years as a training set to construct a screening model for gastrointestinal tumor risk groups.
[0041] The construction method is as follows:
[0042] Step 1, collecting stool samples for constructing a screening model for gastrointestinal tumor risk groups;
[0043] Step 1-1: Collect morning stool samples, mix 5 g of fresh stool with 25 mL of preservation solution, take 4 ml of stool suspension, and centrifuge at 4200 rpm for 20 min.
[0044] Step 1-2: After centrifugation, transfer the supernatant to the 15 mL centrifuge tube prepared above and discard the residue.
[0045] Step 1-3: Add 1 ml of extraction solution I (guanidine isothiocyanate (can quickly break cells and inhibit the release of ribozymes from cells to obtain high-quality DNA)) 47.25 g, sterile purified water 30 mL, 0.5 mol / L ETA (chelates metal ions such as magnesium and calcium, inhibits the degradation of DNA by deoxyribonucleases and is more conducive to the action of lysozyme) 4 mL, 1 mol / L dithiothreitol (DTT) (reducing agent and deprotecting agent for thiol-modified DNA, used to reduce disulfide bonds in proteins) 3.25 mL, TritonX-100 4 mL (non-ionic surfactant, helps to separate protein from DNA), 1 mol / L Tris-HCl (PH6.5) (adjust the pH of the solution to maintain a certain ion concentration) 1 mL, adjust the pH to 6.5, make up to 100 mL with sterile water, and fully dissolve), gently shake to mix, insert the centrifuge tube into the plate, and incubate at 65°C for 20 min. (Prepare ice boxes during this period, and use foam boxes to store ice after making it)
[0046] Step 1-4: Add an equal volume of anhydrous ethanol (DNA precipitant, ethanol will take away the water molecules around DNA, making DNA dehydrated and easy to aggregate) (pre-cool the anhydrous ethanol at -20° before the experiment), mix gently, and centrifuge at 5000rpm in a refrigerated centrifuge for 20 minutes. Discard the supernatant and keep the precipitate (about 1-2mL) for subsequent purification.
[0047] Step 1-5: Add 600-800uL of extraction solution II (573.18g guanidine hydrochloride dissolved in 1000ml ddH20) (denaturant, guanidine hydrochloride solution can dissolve proteins, causing cell structure damage, nucleoprotein secondary structure damage, and dissociation from nucleic acids) to the above precipitate, shake and mix until the precipitate disappears (if the precipitate is difficult to disperse, heat it at 56°C until the precipitate disappears).
[0048] Step 1-6: Transfer the above digestion solution to the DNA adsorption column several times, let it stand at room temperature for 2 minutes, centrifuge at 10000 rpm for 1 minute, and discard the waste liquid.
[0049] Step 1-7: Add 600uL of 75% ethanol to the center of the column (to precipitate DNA and dissolve salt ions that may be bound to DNA), centrifuge at 10000rpm for 30S, and remove the waste liquid.
[0050] Step 1-8: Repeat the above steps once (if the solution is still very yellow after rinsing, add 600L 75% ethanol for rinsing).
[0051] Step 1-9: Centrifuge the DNA adsorption column at 10,000 rpm for 2 minutes.
[0052] Step 1-10: First elution: Place the centrifuge column in a clean 1.5 mL centrifuge tube, label the sample name, open the cap of the centrifuge column, and place it at room temperature for 3-5 minutes (to evaporate residual ethanol). Then add 100 μL of 75°C preheated DNA dissolving solution (ATE or Elution buffer) to the center of the column, place it at room temperature for 5 minutes, and centrifuge at 10,000 rpm for 2 minutes to obtain the DNA sample solution.
[0053] Step 1-11: Second elution: Place the centrifuge column in another clean 1.5 mL centrifuge tube again, label the sample name, open the cap of the centrifuge column, and then add 100 μL of 75°C preheated DNA dissolution solution (ATE or Elution buffer) to the center of the column, place at room temperature for 5 minutes, centrifuge at 10,000 rpm for 2 minutes, and obtain the DNA sample solution (Note: After eluting the DNA, the DNA adsorption column can be retained and eluted again later).
[0054] Steps 1-12: The extracted DNA was subjected to sulfite conversion using a commercial kit, Zymo D5006 kit.
[0055] Step 2, using a stool DNA methylation detection reagent to perform qPCR detection on the stool samples collected in step 1 to obtain the Ct value of the stool DNA of each sample;
[0056] The amplification system and amplification conditions are as follows:
[0057] Combination 1:
[0058] Primer probe name Concentration (μM) Addition volume (μL) PDX1-Me-PF 10 0.08 PDX1-Me Probe(ROX) 10 0.08 PDX1-Me-PR 10 0.08 GAPDH Meth Primer F 5 0.06 GAPDH Meth Primer R 5 0.06 GAPDH Meth Probe(CY5) 5 0.08 Bis-DNA / 2 2×Epitect Methylight master mix / 6 RNase-Free Water / 1.56 Total Volume / 10
[0059] Combination 2
[0060]
[0061]
[0062] Amplification conditions:
[0063] Step 3, calculate the ΔCt value, ΔCt=Ct(target gene)-Ct(GAPDH), and perform scoring.
[0064] Evaluation criteria:
[0065] The △Ct value scores of the three target genes obtained in step 3 are used. If the △Ct value score of any target gene is less than 10, the patient is judged to be a gastrointestinal tumor risk group.
[0066] To validate the model, an additional 124 untreated patients with histologically diagnosed gastrointestinal tumors and 92 healthy controls who underwent gastrointestinal tumor-related examinations every 3 years were recruited as a test set.
[0067] The results showed that 98 of 124 patients (79%) tested positive, and 88 of 92 healthy controls (96%) tested negative. The sensitivity of colorectal cancer (CRC, 24 / 34), gastric cancer (GC, 19 / 23), esophageal cancer (EC, 18 / 24), pancreatic cancer (PC, 17 / 21) and ampullary cancer (AC, 20 / 22) in each gastrointestinal cancer type was 71%, 83%, 75%, 81% and 91%, respectively. In addition, among the 4 positive healthy controls, 3 were diagnosed with advanced adenomas and 1 was a pregnant woman.
[0068] Example 3: Construction of Model 2
[0069] This study recruited 124 untreated patients with histological diagnosis of gastrointestinal tumors and 92 healthy controls who underwent gastrointestinal tumor-related examinations every 3 years as a training set to construct a screening model for gastrointestinal tumor risk groups.
[0070] The construction method is as follows:
[0071] Step 1 to step 3 are the same as in Example 2.
[0072] Step 4: Use the △Ct value obtained in step 3 to construct a machine learning model, use the multivariate logistic regression model to establish a single cancer diagnosis model, and set relevant thresholds to obtain diagnostic models for five gastrointestinal tumors: CRC, GC, EC, PC, and AC.
[0073] To validate the model, an additional 124 untreated patients with histologically diagnosed gastrointestinal tumors and 92 healthy controls who underwent gastrointestinal tumor-related examinations every 3 years were recruited as a test set.
[0074] The results showed that 112 of 124 patients (90%) tested positive, and 88 of 92 healthy controls (96%) tested negative. In the CRC model, the sensitivity for CRC was 88% (30 / 34). In the GC model, the sensitivity for GC was 91% (21 / 23). In the EC model, the sensitivity for EC was 88% (21 / 24). In the PC model, the sensitivity for PC was 90% (19 / 21). In the AC model, the sensitivity for AC was 95% (21 / 22).
[0075] It can be seen that multi-target fecal DNA methylation detection has a high sensitivity and can accurately detect and identify the tissue of origin of gastrointestinal tumors at an early stage.
[0076] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed. However, as long as it is within the scope of the claims of the present application, it shall be protected by the patent law.
Claims
1. Application of a stool DNA methylation detection reagent in the preparation of a digestive tract tumor diagnosis product, characterized in that: The reagents include the following combinations of multiple primer pairs: The primer pair used to detect the PDX1 gene, the sequences of which are shown in SEQ ID NOs. 1 to 2; The primer pair used to detect the COL4A2-1 gene, whose sequences are shown in SEQ ID NOs. 4 to 5; The primer pair used to detect the FGF5 gene has sequences shown in SEQ ID NOs. 7-8.
2. The use according to claim 1, characterized in that: The reagents also include a combination of the following probes: A probe for detecting the PDX1 gene, the sequence of which is shown in SEQ ID NO.3; A probe for detecting COL4A2-1 gene, the sequence of which is shown in SEQ ID NO.6; The sequence of the probe used to detect the FGF5 gene is shown in SEQ ID NO.
9.
3. The use according to claim 1, characterized in that: The reagent also includes a primer pair for detecting the internal reference gene GAPDH, and the sequence thereof is shown in SEQ ID NOs. 10-11.
4. The use according to claim 3, characterized in that: The reagent also includes a probe for detecting an internal reference gene GAPDH, the sequence of which is shown in SEQ ID NO.
12.
5. A digestive tract tumor diagnosis product, characterized in that: The invention comprises the stool DNA methylation detection reagent according to any one of claims 1 to 4.
6. A method for constructing a screening model for gastrointestinal tumor risk groups, characterized in that: The following steps are involved: Step 1, collecting stool samples for constructing a screening model for gastrointestinal tumor risk groups; Step 2, using the stool DNA methylation detection reagent according to any one of claims 1 to 4 to perform qPCR detection on the stool samples collected in step 1 to obtain the Ct value of the stool DNA of each sample; Step 3, calculate the ΔCt value, ΔCt=Ct(target gene)-Ct(GAPDH), and perform scoring.
7. The construction method according to claim 6, characterized in that: The following steps are also included: Step 4, use the △Ct value obtained in step 3 to build a machine learning model, use a multivariate logistic regression model to build a model, and set relevant thresholds to obtain a screening model for people at risk of gastrointestinal tumors.
8. Use of the model obtained by the modeling method described in claim 6 or 7 in the preparation of digestive tract tumor diagnosis products.
9. A digestive tract tumor diagnosis system, characterized in that: include: Data module: used to obtain the △Ct value data of qPCR of fecal DNA of the sample to be tested Scoring module: obtaining the score of the sample to be tested by the model obtained by the modeling method described in claim 6 or 7; Judgment module: Use the threshold to judge the score of the sample to be tested. If it is greater than the threshold, it is judged as positive, and if it is less than the threshold, it is judged as negative.
